Geldanamycin is a natural product and an antibiotic with anti-tumor properties. It was first discovered in 1970 from the bacterium Streptomyces hygroscopicus, which is commonly found in soil. Geldanamycin belongs to the class of molecules known as ansamycins, which are known for their ability to bind to and inhibit heat shock protein 90 (HSP90), a molecular chaperone that plays a role in cancer cell proliferation and survival.
Chemical name:
The chemical name for Geldanamycin is 5'-demethoxy-5'-nor-geldanamycin.
Molecular formula:
The molecular formula of Geldanamycin is C29H40N2O8.
Formula weight:
The formula weight of Geldanamycin is 560.65 g/mol.
CAS No:
The CAS number of Geldanamycin is 30562-34-6.
Top ten keywords from Google and Synonyms:
Synonyms:
Health benefits of this product:
Geldanamycin has been primarily developed for the treatment of cancer. It is a selective inhibitor of HSP90, which plays an important role in the stabilization of oncogenic proteins and is often overexpressed in cancer cells. By inhibiting HSP90, Geldanamycin may help to destabilize these oncogenic proteins and slow or stop the growth of cancer cells.
Potential effects:
Some potential effects of Geldanamycin include:
Product mechanism:
Geldanamycin works by binding to the ATP-binding pocket of HSP90, which is a chaperone protein that plays an important role in the folding and stability of other proteins. HSP90 is often overexpressed or mutated in cancer cells, leading to their uncontrolled growth and survival. By inhibiting HSP90, Geldanamycin may help to destabilize the oncogenic proteins that are dependent on HSP90 for their stability and function, and slow or stop the growth of cancer cells.
Safety:
Geldanamycin has been tested in preclinical and clinical studies for its safety profile. The drug has been found to have acceptable toxicity and has not shown any significant adverse effects on normal tissues or organs. However, as with any medication, there are some risks associated with its use. Patients should inform their healthcare provider of any pre-existing medical conditions or medications they are taking before starting treatment with Geldanamycin.
Side effects:
Geldanamycin can cause several side effects in some patients. These can include:
Dosing information:
The optimal dosing regimen of Geldanamycin has not yet been established and further research is needed to determine the most effective dose. In preclinical studies, doses ranged from 0.01 to 100 μM. In clinical trials, doses ranged from 17.5 to 450 mg/m2 per day. The drug is typically administered intravenously.
Conclusion:
Geldanamycin is a natural product and an antibiotic that has shown potential as a treatment for cancer. By inhibiting HSP90, Geldanamycin may help to destabilize oncogenic proteins and slow or stop the growth of cancer cells. The drug has undergone several preclinical and clinical trials and has been found to have an acceptable safety profile. However, as with any medication, there are some risks associated with its use. Further research is needed to determine the optimal dosing regimen and efficacy of Geldanamycin in treating cancer
